Advertisement

Topics

Jaguar Health Subsidiary Napo Pharmaceuticals, Inc. Receives Orphan-Drug Designation For Mytesi (Crofelemer) For Treatment Of Short Bowel Syndrome

20:00 EDT 6 Aug 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Jaguar Health Subsidiary Napo Pharmaceuticals, Inc. Receives Orphan-Drug Designation For Mytesi (Crofelemer) For Treatment Of Short Bowel Syndrome

NEXT ARTICLE

More From BioPortfolio on "Jaguar Health Subsidiary Napo Pharmaceuticals, Inc. Receives Orphan-Drug Designation For Mytesi (Crofelemer) For Treatment Of Short Bowel Syndrome"

Quick Search
Advertisement